Business Wire11.06.18
Shape Memory Medical Inc. has hired Scott Kraus as vice president of Sales and Business Development. Kraus most recently served as area vice president–East for Intersect ENT, a position he has held since October of 2014. Prior to this role, Kraus had similar senior management roles at TriReme Medical, Intact Vascular, and Cardiovascular Systems Inc. Kraus's career also includes positions at Guidant, C.R. Bard, Bristol Myers Squibb, and Surgical Specialties Corporation. Kraus earned a bachelor of science degree from Villanova University and an MBA from St. Joseph’s University.
“Scott’s background in sales growth, product launch, and strategic planning and experience in many medical specialties will allow him to immediately enhance and execute our commercial strategy in Europe and the United States for our peripheral and neurovascular polymer embolization devices,” said CEO Ted Ruppel. “Hiring someone of Scott’s caliber and experience is a milestone for Shape Memory, and a testament to the unique products that have been designed and tested by our skilled research and development team.”
Commenting on his new position, Scott said, “I have been impressed by the Shape Memory Medical team and their ability to develop a differentiated product platform. The IMPEDE Embolization Plug along with the Trellix Embolic Coil and other products in development, will offer physicians more versatility, improved clinical outcomes and transform the treatment for millions of patients suffering from vascular disease.”
Shape Memory Medical Inc., based in Santa Clara, Calif., develops multiple medical therapies with its Shape Memory Polymers for embolization. These products include IMPEDE Embolization Plugs to obstruct or reduce the rate of blood flow in the peripheral vasculature (CE Marked and cleared by the U.S. Food and Drug Administration). The company’s TrelliX Embolic Coils have not been cleared or approved by FDA, and are not commercially available.
“Scott’s background in sales growth, product launch, and strategic planning and experience in many medical specialties will allow him to immediately enhance and execute our commercial strategy in Europe and the United States for our peripheral and neurovascular polymer embolization devices,” said CEO Ted Ruppel. “Hiring someone of Scott’s caliber and experience is a milestone for Shape Memory, and a testament to the unique products that have been designed and tested by our skilled research and development team.”
Commenting on his new position, Scott said, “I have been impressed by the Shape Memory Medical team and their ability to develop a differentiated product platform. The IMPEDE Embolization Plug along with the Trellix Embolic Coil and other products in development, will offer physicians more versatility, improved clinical outcomes and transform the treatment for millions of patients suffering from vascular disease.”
Shape Memory Medical Inc., based in Santa Clara, Calif., develops multiple medical therapies with its Shape Memory Polymers for embolization. These products include IMPEDE Embolization Plugs to obstruct or reduce the rate of blood flow in the peripheral vasculature (CE Marked and cleared by the U.S. Food and Drug Administration). The company’s TrelliX Embolic Coils have not been cleared or approved by FDA, and are not commercially available.